FXS5626 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

4 results for “FXS5626”

Trials

Not yet recruiting

QT Interval Effects Study of Oral FXS5626 Tablets

28 participants · First posted Jul 10, 2026

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU

40 participants · First posted Apr 27, 2026

News

Accro Bioscience Secures China Regulatory Clearance for Vitiligo Trial

Accro Bioscience Announces NMPA Clearance for Phase II/III Trial of AC-201, a Selective TYK2/JAK1 Inhibitor for Non-Segmental Vitiligo